Expression of PLK1 and survivin in diffuse large B-cell lymphoma

Abstract

Polo-like kinase 1 (PLK1) belongs to a conservative family of serine/threonine kinase and plays an important role in the process of cell cycle. Survivin is a member of inhibitor of apoptosis protein (IAP) family. We investigated the expression of PLK1 and survivin with immunohistochemical techniques in diffuse large B-cell lymphoma (DLBCL) and assessed their significance as a potent new tumor marker. The expression rate of PLK1 and survivin were 66.7% (26/39) and 82.1% (32/39), respectively. PLK1 expression correlated with systemic symptom, LDH level, IPI scores and therapeutic effect in DLBCL, while survivin did not. PLK1 expression correlated with shortened event-free survival (EFS) using the Log-rank test in DLBCL, but survivin did not. Cox regression analysis identified the independent prognostic significance for PLK1. The results suggest that there is a significant relationship between over expression of PLK1, the clinical features and survival time. Compared with survivin, PLK1 seems to be a better independent prognostic factor for DLBCL.